Eléments de l'association

	Sumanta Pal	1
	Antineoplastic Combined Chemotherapy Protocols (therapeutic use)	22
	Sumanta Pal *Sauf* Antineoplastic Combined Chemotherapy Protocols (therapeutic use)"	0
	Antineoplastic Combined Chemotherapy Protocols (therapeutic use) *Sauf* Sumanta Pal"	21
	Sumanta Pal Et Antineoplastic Combined Chemotherapy Protocols (therapeutic use)	1
	Sumanta Pal Ou Antineoplastic Combined Chemotherapy Protocols (therapeutic use)	22
	*Corpus*	3114

List of bibliographic references

Number of relevant bibliographic references: 1.

Ident.	Authors (with country if any)	Title
000746	Toni K. Choueiri [États-Unis] ; Bernard Escudier [France] ; Thomas Powles [Royaume-Uni] ; Nizar M. Tannir [États-Unis] ; Paul N. Mainwaring [Australie] ; Brian I. Rini [États-Unis] ; Hans J. Hammers [États-Unis] ; Frede Donskov [Danemark] ; Bruce J. Roth [États-Unis] ; Katriina Peltola [Finlande] ; Jae Lyun Lee [Corée du Sud] ; Daniel Y C. Heng [Canada] ; Manuela Schmidinger [Autriche] ; Neeraj Agarwal [États-Unis] ; Cora N. Sternberg [Italie] ; David F. Mcdermott [États-Unis] ; Dana T. Aftab [États-Unis] ; Colin Hessel [États-Unis] ; Christian Scheffold [États-Unis] ; Gisela Schwab [États-Unis] ; Thomas E. Hutson [États-Unis] ; Sumanta Pal [États-Unis] ; Robert J. Motzer [États-Unis]	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024